NNT
protein-codingnicotinamide nucleotide transhydrogenase
Gene summary
This gene encodes an integral protein of the inner mitochondrial membrane. The enzyme couples hydride transfer between NAD(H) and NADP(+) to proton translocation across the inner mitochondrial membrane. Under most physiological conditions, the enzyme uses energy from the mitochondrial proton gradient to produce high concentrations of NADPH. The resulting NADPH is used for biosynthesis and in free radical detoxification. [provided by RefSeq, Sep 2016]
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~104.7 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: AR
Disease ID:MONDO:0013874
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AR
Disease ID:MONDO:0013874
Submitter: PanelApp Australia
Inheritance Pattern: AR
Disease ID:MONDO:0008733
Submitter: Orphanet
Inheritance Pattern: AR
Disease ID:MONDO:0044970
Submitter: ClinGen
The relationship between *NNT* and primary mitochondrial disease was evaluated using the ClinGen Clinical Validity Framework as of July 15, 2024. The *NNT* gene encodes nicotinamide nucleotide transhydrogenase, a pyridine nucleotide transhydrogenase found in the inner mitochondrial membrane, and catalyzes the transfer of hydride ions between NAD(H) and NADP(H). *NNT* was first reported in relation to autosomal recessive primary mitochondrial disease in 2012 (PMID: 22634753). While various names have been given to the constellation of features seen in those with *NNT*-related disorders, including glucocorticoid deficiency, pathogenic variants in this gene cause a primary mitochondrial disease. Therefore, the NNT phenotype has been lumped into one disease entity according to the ClinGen Lumping and Splitting Framework. Evidence supporting this gene-disease relationship includes case-level data and experimental data. This curation included nine variants (three missense, six nonsense or frameshift), in ten cases from ten publications (PMIDs: 22634753, 26070314, 26548497, 25459914, 38261461, 27129361, 35627102, 36478070, 26523528, 37352919). Clinical features in affected individuals include glucocorticoid deficiency, ptosis, hypertrophic cardiomyopathy, epilepsy and hypoglycemic seizures, developmental delay, and cardiac arrest. The mechanism of disease is loss of function. This gene-disease association is also supported by its expression in adrenal tissue, and skeletal muscle, liver tissue, and heart, and functional alteration and rescue in non-patient cells (PMIDs: 34321199, 22634753, 36478070). Of note, there is a mouse model of this disorder showing phenotypic overlap with glucocorticoid deficiency (PMIDs: 23747984, 29046340) and a congenic mouse model shows an age-dependent effect on skeletal muscle in mice with Nnt knockout (PMID: 38795789). Evidence regarding cardiomyopathy in Nnt knockout mice is contested (PMID: 32213617) and therefore mouse cardiomyopathy phenotypes were not included in this curation. In summary, there is definitive evidence to support the relationship between *NNT* and primary mitochondrial disease. This relationship has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Gene Curation Expert Panel on July 15, 2024 (SOP Version 10).
Inheritance Pattern: AR
Disease ID:MONDO:0013874
Submitter: Ambry Genetics
Clinical Genomic Database (CGD)
Manifestation: Cardiovascular; Endocrine
Intervention: Cardiovascular; Endocrine
Rationale: The condition can involve early-onset life-threatening sequelae of glucocorticoid deficiency as well as later effects involving mineralocorticoid deficiency and other manifestations (eg, possible thyroid and cardiac findings) and awareness may allow preventive/treatment measures (eg, with corticosteroid replacement therapy) related to adrenal insufficiency
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to NNT variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_182977.3. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 1 | 58 | 6 | 65 | ||
| missense | 6 | 5 | 157 | 10 | 3 | 181 |
| nonsense | 3 | 2 | 5 | |||
| start loss | 0 | |||||
| frameshift | 7 | 7 | 14 | |||
| splice donor/acceptor (+/-2bp) | 3 | 3 | 6 | 12 | ||
| Total | 19 | 17 | 164 | 68 | 9 | 277 |
Highest pathogenic variant AF is 0.000009109058
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_892022.2 | 21 | MANE Select | |
| Ensembl | ENSP00000343873.4 | 21 | MANE Select | |
| RefSeq | NP_001317955.1 | 19 | Standard | |
| RefSeq | NP_036475.3 | 21 | Standard |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- Nicotinate and nicotinamide metabolism - Homo sapiens (human)
- Nicotinate and Nicotinamide Metabolism
- Citric acid cycle (TCA cycle)
- Pyruvate metabolism and Citric Acid (TCA) cycle
- The citric acid (TCA) cycle and respiratory electron transport
Biological Process
- negative regulation of protein phosphorylation
- tricarboxylic acid cycle
- NADPH regeneration
- positive regulation of mitochondrial membrane potential
- oxygen homeostasis
Molecular Function
- NAD(P)+ transhydrogenase (B-specific) activity
- NAD(P)+ transhydrogenase activity
- NADP binding
- NAD binding
Cellular Component
- mitochondrion
- mitochondrial inner membrane
- mitochondrial respirasome
- membrane
- integral component of membrane
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000264663
- Coding exons
- 21
- Length
- 104714
- Individuals with no LoFs
- 125727
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 21
- Defined
- 125748
- p
- 0.0000835
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 2.08 | 448 | 591 | 0.759 | 0.0000298 | 6969 |
| Missense (PolyPhen) | 174 | 272.41 | 0.63874 | 3166 | ||
| Synonymous | 0.480 | 217 | 226 | 0.959 | 0.0000126 | 2302 |
| Loss of Function | 5.22 | 8 | 46.4 | 0.172 | 0.00000253 | 576 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0.00018 | 0.00018 | rare |
| Latino/Admixed American | 0.000095 | 0.000087 | rare |
| Ashkenazi Jewish | 0.00020 | 0.000099 | rare |
| East Asian | 0.00011 | 0.00011 | rare |
| Finnish | 0.000093 | 0.000092 | rare |
| European (Non-Finnish) | 0.000072 | 0.000070 | rare |
| South Asian | 0.000065 | 0.000065 | rare |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: The transhydrogenation between NADH and NADP is coupled to respiration and ATP hydrolysis and functions as a proton pump across the membrane. May play a role in reactive oxygen species (ROS) detoxification in the adrenal gland. {ECO:0000269|PubMed:22634753}.;
Recessive Scores
- pRec
- 0.0918
Intolerance Scores
- LoFtool
- 0.0186
- RVIS EVS
- -0.39
- RVIS percentile EVS
- 27.03
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.996
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |